Clinical Trials Go Local: Lightship Acquires Veda, Bringing Research to Community Clinics

RESEARCH TRIANGLE PARK, N.C. – February 04, 2026 – In a significant move to reshape the landscape of medical research, Lightship Inc. today announced its acquisition of Veda Trials. The deal merges Lightship's modern clinical trial site network with Veda's specialized technology for embedding research operations within community healthcare settings, creating a powerful new model designed to make clinical trial participation more accessible, diverse, and efficient.

The acquisition aims to tackle some of the most persistent challenges in drug development: slow patient recruitment and a lack of diversity among trial participants. By combining their strengths, the new entity intends to accelerate the delivery of new therapies by bringing research directly into the neighborhood clinics and homes of patients across the United States.

A New Front Line for Patient Access and Equity

For decades, the gold standard for clinical research has been the large academic medical center, a model that often excludes vast segments of the population. With an estimated 70% of potential participants living more than two hours from these specialized sites, geography has become a primary barrier to access. This acquisition represents a deliberate strategy to dismantle that barrier.

By integrating Veda Trials' network of community-based clinics—including specialists in women’s health, dermatology, and allergy/asthma—Lightship can now offer sponsors unprecedented reach into real-world care environments. This shift is about more than just convenience; it's a foundational move toward health equity. By meeting patients where they are, the company can engage populations that have been historically underrepresented in clinical research, a critical step for developing drugs that are safe and effective for everyone.

Lightship has already demonstrated a commitment to this goal. In a recent cardiology trial, the company successfully recruited 37% of participants who identified as Black, a dramatic increase from the industry average of 6% for such studies. The combined capabilities of Lightship and Veda are expected to scale these results, leveraging a participant-first model that offers flexible visit options, including on-site, near-home via mobile research units, and fully in-home care. This hybrid approach significantly reduces the travel and time burden on participants, which is expected to improve both recruitment and long-term retention in studies.

A Strategic Play in the Booming Decentralized Trial Market

The Lightship-Veda deal is not just a win for patients; it's a calculated business maneuver in the rapidly expanding Decentralized Clinical Trial (DCT) market. Industry analysts project the DCT market to grow from approximately $10.7 billion in 2026 to over $21 billion by 2031, fueled by technological advancements and a major regulatory push. Recent guidance from the FDA has provided clearer pathways for using remote monitoring, telehealth, and local care networks, encouraging the very model this acquisition champions.

By acquiring Veda Trials, Lightship solidifies its position as a leader in this evolving space. The merger creates a single, integrated platform that offers pharmaceutical sponsors and contract research organizations (CROs) a streamlined solution for faster trial start-up and execution. Veda Trials, which was originally backed by venture capital firm Redesign Health, developed technology specifically to reduce the operational friction that prevents busy community clinics from participating in research. Integrating this technology with Lightship's established site network and mobile services creates powerful operational synergies.

Strategic benefits highlighted by the companies include compressed timelines from study feasibility to enrolling the first patient, consistent data quality through standardized operating procedures (SOPs), and a broader, more representative participant pool. In a competitive market where speed and diversity are paramount, this combined offering presents a compelling value proposition that could set a new industry standard and influence future M&A activity in the clinical research sector.

Weaving Technology into the Fabric of Community Care

At the heart of this acquisition is the fusion of technology and community healthcare. Veda Trials built its reputation by creating a platform that simplifies the complexities of clinical research for local providers. Its technology streamlines everything from site activation to daily study workloads, allowing clinics to integrate research into their existing workflows without hiring extensive new staff or overwhelming their teams. This tech-enabled approach is crucial for scaling research beyond traditional institutions.

Under the new structure, Veda's capabilities will be woven into Lightship's broader operational framework. The integration plan focuses on aligning SOPs and training across the networks, accelerating the activation of existing Veda partner clinics, and offering sponsors comprehensive service packages. These packages will span patient outreach, site operations, mobile care, and home visits, all managed through a unified system.

For community clinics, this partnership offers a chance to participate in cutting-edge medical science, provide patients with new treatment options, and generate additional revenue without significant upfront investment or operational overhaul. By embedding experienced research staff and fit-for-purpose technologies, the combined entity aims to maintain rigorous data quality and integrity while reducing the burden on local providers, making research a viable and attractive option for practices of all sizes.

Leadership and the Path Forward

To ensure a seamless transition, the Veda Trials team will join Lightship, with founder and CEO Lesley Solomon continuing in her role and reporting to Lightship CEO David MacMurchy. This continuity is designed to maintain momentum and reassure existing partners and clients that active studies will proceed without disruption.

“This acquisition advances our mission to increase access, choice, and equity in clinical research,” said David MacMurchy in the official announcement. “By combining Veda’s community-based operations model with Lightship’s site network, hybrid delivery model, and mobile research services, we’ll help sponsors launch trials faster and reach more representative participant populations while maintaining our high standards of quality and data integrity.”

Lesley Solomon echoed this vision, emphasizing the practical benefits for providers. “Veda was founded to make clinical research workable for real-world clinics,” she stated. “By simplifying operations with technology that fits into everyday care, we help providers run trials without added complexity. Together with Lightship, we can scale that model nationally while preserving the execution quality sponsors expect.”

The integration process is already underway, with a focus on creating a unified operational playbook that delivers consistent quality across a vastly expanded network. As the worlds of technology and healthcare continue to converge, this merger signals a pivotal evolution in drug development—one where the next medical breakthrough might just begin at your local doctor’s office.